Metycylinooporne gronkowce zlociste [MRSA] o wysokiej opornosci na mupirocyne w szpitalach regionu gdanskiego

• Autorzy: Wisniewska K. , Dajnowska-Stanczewa A. , Galinski J. , Garbacz K.
• Języki publikacji: PL

Abstrakty

PL

W regionie gdańskim, w latach 1997-2000, szczepy o wysokiej oporności na mupirocynę stanowiły 4,7% MRSA. Wyizolowano je w 3 spośród 18 szpitali, ogółem u 6 pacjentów. Szczepy te charakteryzowały się wysokim stopniem oporności na metycylinę, były oporne na większość antybiotyków, za wyjątkiem glikopeptydów i bacytracyny i najprawdopodobniej pochodziły z tego samego źródła.

EN

Occurence of high - level mupirocin resistace in methicillin - resistant Staphylococcus aureus (MRSA) strains isolated from 18 hospitals in Gdańsk area was determined. The study was carried out on 190 MRSA isolated in 1997 - 2000 from various clinical samples. The strains were tested for high - level mupirocin resistance by 200 μg mupirocin disc. The minimum inhibitory concentrations (MIC) for methicillin were estimated by agar dilution. Sensivity to other antibiotics was determined in disc - diffusion method and to vancomycin in agar dilution method additionally. The strains were typed by set of 10 experimental phages and compared by the metod of PCR - RFLP analysis of coagulase gen restriction fragment lenght polymorphism. There were low frequency of high - level mupirocin resistance in MRSA strains (4,7%) that were found only in 3 hospitals, in 6 patients. All of them were high - resistant also to methicillin and resistant to doxycyclin, gentamycin, erytromycin, klindamycin, ciprofloksacin, rifampicin, resistant or intermediate sensitive to fusidic acid but sensitive to vancomycin, teikoplanin and bacitracin. The origin all of the MRSA strains high - resistant to mupirocin probably was the same except one strain, because they were belonged to one genetic type and possessed the phage pattern.

Słowa kluczowe

PL

region gdanski; szpitale; opornosc na mupirocyne; gronkowiec zlocisty; opornosc na antybiotyki; zakazenia szpitalne

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2002
• Tom: 54
• Numer: 4
• Opis fizyczny: s.285-292,tab.,bibliogr.

Twórcy

autor

Wisniewska K.

• Akademia Medyczna, Gdansk

autor

Dajnowska-Stanczewa A.

autor

Galinski J.

autor

Garbacz K.

Bibliografia

• 1. Barski P, Piechowicz L, Galiński J, Kur J. Rapid assay for detection of methicillin-resistant Staphylococcus aureus using multiplex PCR. Molec Cellul Probs 1996; 10: 471-75.
• 2. Blair JE, Williams REO. Phage typing of staphylococci. WHO Biulletin 1961; 24: 771-78.
• 3. Courvalin P, Soussy C - J [eds]. Report of the Comité de l'Antibiogramme de la Société Française de Microbiologie. Clin Microbiol Infect 1996; Vol 2. Suppl. 1: 46-49.
• 4. de Neeling AJ, van Leeuven WJ, Schouls LM i inni. Resistance of staphylococci in the Netherlands: surveillance by an electronic network during 1989-1995. J Antimicrob Chemother 1998: 41: 93-101.
• 5. Garbacz K, Piechowicz L, Wiśniewska K, Galiński J. Charakterystyka metycylinoopornych gronkowców złocistych (MRSA) regionu gdańskiego w oparciu o polimorfizm genu koagulazy. Med Dośw Mikrobiol 2001; 53: 311-19.
• 6. Hryniewicz W, Trzciński K, Krzysztoń-Russjan J, Gniadkowski M. Zasady doboru testów wrażliwości bakterii na antybiotyki i chemioterapeutyki. Mikrobiologia Medycyna 1999; 2: 12-16.
• 7. Koss WE, Schleifer KH. Simplified scheme for routine identification of human Staphylococcus species. J Clin Microbiol 1975; 1: 82-88.
• 8. Lang S, Raymond N, Brett M. Mupirocin resistant Staphylococcus aureus in Auckland. New Zealand Med J 1992; 105: 438.
• 9. Łęski T, Gronkowce oporne na mupirocynę. Epidemiologia i molekularne mechanizmy oporności. Post Mikrobiol 1998; XXXVII, 3: 289-303.
• 10. Naguib MH, Naguib MT, Flournoy DJ. Mupirocin resistance in methicillin – resistant Staphylococcus aureus from a veterans hospital. Chemotherapy (Basel) 1993; 39: 400-404.
• 11. NCCLS: National Comittee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. 3 rd ed. 1994.
• 12. NCCLS: National Committee for Clinical Laboratory Standards. 1998. Vol 18. No 1. Doc M100-S8. Tab 2 C.
• 13. Perl TM, Golub JE. New approaches to reduce Staphylococcus aureus nosocomial infection rates: Treating S. aureus nasal carriage. Annals of Pharmacotherapy 1998; 32: 7-16.
• 14. Rahman M, Noble WC, Cookson B. Mupirocin - resistant Staphylococcus aureus. Lancet 1987; 2: 387
• 15. Schmitz FJ, Lindenlaf E, Hofmann B i inni. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 1998; 42: 489-95.
• 16. Soto N.E, Vaghjimal A, Stahl-Avicolli A i inni. Bacitracin versus mupirocin for Staphylococcus aureus nasal colonization. Infect Control Hosp Epidemiol 1999; 20: 351-53.
• 17. Sutherland R, Boon RJ, Griffin KE i inni. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother 1985; 27: 495-98.
• 18. Trzciński K, Hryniewicz W, Kluytmans J i inni. Simultaneous persistence of methicillin-resistant and methicillin susceptibilie clones of Staphylococcus aureus in a neonatal ward of Warsaw Hospital. J Hosp Infect 1997; 36: 291-303.
• 19. Udo EE, Pearman JW, Grubb WB. Emergence of high-level mupirocin resistance methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1994; 26: 157-65.
• 20. Wise R, Johnson J. Mupirocin resistance. Lancet 1991; 338: 578.